APA

Karp J. E., Garrett-Mayer E., Estey E. H., Rudek M. A., Smith B. D., Greer J. M., Drye D. M., Mackey K., Dorcy K. S., Gore S. D., Levis M. J., McDevitt M. A., Carraway H. E., Pratz K. W., Gladstone D. E., Showel M. M., Othus M., Doyle L. A., Wright J. J. & Pagel J. M. (20131107). Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. : Haematologica.

Chicago

Karp Judith E, Garrett-Mayer Elizabeth, Estey Elihu H, Rudek Michelle A, Smith B Douglas, Greer Jacqueline M, Drye D Michelle, Mackey Karen, Dorcy Kathleen Shannon, Gore Steven D, Levis Mark J, McDevitt Michael A, Carraway Hetty E, Pratz Keith W, Gladstone Douglas E, Showel Margaret M, Othus Megan, Doyle L Austin, Wright John J and Pagel John M. 20131107. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. : Haematologica.

Harvard

Karp J. E., Garrett-Mayer E., Estey E. H., Rudek M. A., Smith B. D., Greer J. M., Drye D. M., Mackey K., Dorcy K. S., Gore S. D., Levis M. J., McDevitt M. A., Carraway H. E., Pratz K. W., Gladstone D. E., Showel M. M., Othus M., Doyle L. A., Wright J. J. and Pagel J. M. (20131107). Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. : Haematologica.

MLA

Karp Judith E, Garrett-Mayer Elizabeth, Estey Elihu H, Rudek Michelle A, Smith B Douglas, Greer Jacqueline M, Drye D Michelle, Mackey Karen, Dorcy Kathleen Shannon, Gore Steven D, Levis Mark J, McDevitt Michael A, Carraway Hetty E, Pratz Keith W, Gladstone Douglas E, Showel Margaret M, Othus Megan, Doyle L Austin, Wright John J and Pagel John M. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. : Haematologica. 20131107.